Cover Image
市場調查報告書

PharmaPoint:黃斑部水腫 (ME) 和黃斑部病變 (MD) - EU5個國家的醫藥品市場到2023年前的預測與市場分析

PharmaPoint: Macular Edema and Macular Degeneration - 5EU Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325947
出版日期 內容資訊 英文 274 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:黃斑部水腫 (ME) 和黃斑部病變 (MD) - EU5個國家的醫藥品市場到2023年前的預測與市場分析 PharmaPoint: Macular Edema and Macular Degeneration - 5EU Drug Forecast and Market Analysis to 2023
出版日期: 2014年10月31日 內容資訊: 英文 274 Pages
簡介

黃斑部水腫(ME)是液體積存黃斑的狀態,會引起視力障礙,甚至嚴重到造成失明。老年性黃斑部病變(AMD)是沒有痛覺的眼睛疾病,造成階段性,不可逆的視力低落,是五十歲以上,已開發國家人民的主要失明原因之一。

本報告提供EU5個國家的黃斑部水腫 (ME) 和黃斑部病變 (MD) 的治療藥市場相關調查分析,提供您疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素·阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 黃斑部病變 (MD) 概要
  • 黃斑部水腫 (ME) 概要

第4章 疾病的管理

  • 診斷和治療概要
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第5章 競爭評估

  • 概要
  • 產品簡介:領導品牌

第6章 未滿足需求和機會

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
  • 初期開發中的有潛力的藥劑
  • 其他開發中的藥物
  • 生技仿製藥

第8章 市場預測

  • 全球市場
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第9章 附錄

圖表

目錄
Product Code: GDHC262CFR

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

The new therapies entering the AMD market will be the main driver of growth in this market, with the wAMD drugs Fovista, squalamine, and abicipar pegol launching into the French market in 2017, 2018, and 2020, respectively. GlobalData estimates that the combined drug sales for ME and AMD in Italy during 2013 reached $348m.

Scope

  • Overview of Macular Edema and Macular Degeneration including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting 5EU Macular Edema and Macular Degeneration market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in 5EU.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Macular Degeneration Overview
    • 3.1.1. Etiology and Pathophysiology
    • 3.1.2. Classification
    • 3.1.3. Symptoms and Diagnosis
  • 3.2. Macular Edema Overview
    • 3.2.1. Etiology and Pathophysiology
    • 3.2.2. Classification
    • 3.2.3. Symptoms and Diagnosis

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Macular Edema Diagnosis
    • 4.1.2. Macular Degeneration Diagnosis
    • 4.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.4. Clinical Practice
  • 4.2. France
  • 4.3. Germany
  • 4.4. Italy
  • 4.5. Spain
  • 4.6. UK

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands
    • 5.2.1. Lucentis (ranibizumab)
    • 5.2.2. Eylea (aflibercept)
    • 5.2.3. Avastin (bevacizumab)
    • 5.2.4. Macugen (pegaptanib sodium)
    • 5.2.5. Visudyne (verteporfin)
    • 5.2.6. Corticosteroid Implants

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Treatment for Dry AMD
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Longer-Acting Anti-VEGF Drug Therapy
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Increased Efficacy of Anti-VEGF Therapy for wAMD
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Less Invasive Drug Formulations
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Awareness and Earlier Patient Diagnosis
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Home Monitoring of AMD Progression
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Abicipar pegol
    • 7.2.2. Fovista
    • 7.2.3. Squalamine
    • 7.2.4. Lampalizumab
    • 7.2.5. Emixustat
  • 7.3. Promising Drugs in Early-Stage Development
    • 7.3.1. Complement Inhibitors
  • 7.4. Other Drugs in Development
  • 7.5. Biosimilars

8. Market Outlook

  • 8.1. Global
    • 8.1.1. Drivers and Barriers - Global Issues
  • 8.2. France
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers
  • 8.3. Germany
    • 8.3.1. Forecast
    • 8.3.2. Key Events
    • 8.3.3. Drivers and Barriers
  • 8.4. Italy
    • 8.4.1. Forecast
    • 8.4.2. Key Events
    • 8.4.3. Drivers and Barriers
  • 8.5. Spain
    • 8.5.1. Forecast
    • 8.5.2. Key Events
    • 8.5.3. Drivers and Barriers
  • 8.6. UK
    • 8.6.1. Forecast
    • 8.6.2. Key Events
    • 8.6.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed ME and AMD Patients
    • 9.4.2. Percentage of Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - High-Prescribers Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: ARM System Classification of AMD
  • Table 2: Symptoms of AMD
  • Table 3: National and International Treatment Guidelines for ME and AMD
  • Table 4: Most Prescribed Drugs for ME and AMD in the 5 EU Markets, 2013
  • Table 5: ME and AMD Disease Management - France
  • Table 6: ME and AMD Disease Management - Germany
  • Table 7: ME and AMD Disease Management - Italy
  • Table 8: ME and AMD Disease Management - Spain
  • Table 9: ME and AMD Disease Management - UK
  • Table 10: Leading Treatments for ME and AMD, 2014
  • Table 11: Product Profile - Lucentis
  • Table 12: Lucentis SWOT Analysis, 2014
  • Table 13: Approval Dates for Eylea
  • Table 14: Product Profile - Eylea
  • Table 15: Eylea - Common Adverse Reactions
  • Table 16: Eylea SWOT Analysis, 2014
  • Table 17: Product Profile - Avastin
  • Table 18: Avastin SWOT Analysis, 2014
  • Table 19: Product Profile - Macugen
  • Table 20: Product Profile - Visudyne
  • Table 21: Visudyne SWOT Analysis, 2014
  • Table 22: Product Profile - Ozurdex
  • Table 23: Product Profile - Iluvien
  • Table 24: Corticosteroid IVT Implants SWOT Analysis, 2014
  • Table 25: Unmet Needs and Opportunities in ME and AMD
  • Table 26: Promising Drugs in Clinical Development for ME and AMD
  • Table 27: Comparison of Drugs in Development for ME and AMD, 2014
  • Table 28: Product Profile - Abicipar pegol
  • Table 29: SWOT Analysis - Abicipar pegol, 2014
  • Table 30: Product Profile - Fovista
  • Table 31: SWOT Analysis - Fovista, 2014
  • Table 32: Product Profile - Squalamine
  • Table 33: SWOT Analysis - Squalamine, 2014
  • Table 34: Product Profile - Lampalizumab
  • Table 35: SWOT Analysis - Lampalizumab, 2014
  • Table 36: Product Profile - Emixustat
  • Table 37: SWOT Analysis - Emixustat, 2014
  • Table 38: Early-Stage Drugs in Clinical Development for ME and AMD, 2014
  • Table 39: ME and AMD Markets - Drivers and Barriers, 2013-2023
  • Table 40: Sales Forecast ($m) for ME in France, 2013-2023
  • Table 41: Sales Forecast ($m) for AMD in France, 2013-2023
  • Table 42: Key Events Impacting Sales for ME and AMD in France, 2013-2023
  • Table 43: ME and AMD Markets - Drivers and Barriers in France, 2013-2023
  • Table 44: Sales Forecast ($m) for ME in Germany, 2013-2023
  • Table 45: Sales Forecast ($m) for AMD in Germany, 2013-2023
  • Table 46: Key Events Impacting Sales for ME and AMD in Germany, 2013-2023
  • Table 47: ME and AMD Markets - Drivers and Barriers in Germany, 2013-2023
  • Table 48: Sales Forecast ($m) for ME in Italy, 2013-2023
  • Table 49: Sales Forecast ($m) for AMD in Italy, 2013-2023
  • Table 50: Key Events Impacting Sales for MME and AMD in Italy, 2013-2023
  • Table 51: ME and AMD Markets - Drivers and Barriers in Italy, 2013-2023
  • Table 52: Sales Forecast ($m) for ME in Spain, 2013-2023
  • Table 53: Sales Forecast ($m) for AMD in Spain, 2013-2023
  • Table 54: Key Events Impacting Sales for ME and AMD in Spain, 2013-2023
  • Table 55: ME and AMD Markets - Drivers and Barriers in Spain, 2013-2023
  • Table 56: Sales Forecast ($m) for ME in the UK, 2013-2023
  • Table 57: Sales Forecast ($m) for AMD in the UK, 2013-2023
  • Table 58: Key Events Impacting Sales for ME and AMD in the UK, 2013-2023
  • Table 59: ME and AMD Markets - Drivers and Barriers in the UK, 2013-2023
  • Table 60: Key Launch Dates
  • Table 61: Key Patent Expiries
  • Table 62: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Anatomy of the Eye and Macula
  • Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
  • Figure 3: Color Fundus Photographs of Dry and Wet AMD
  • Figure 4: FAF Imaging of GA
  • Figure 5: Imaging of wAMD
  • Figure 6: CMT in DME
  • Figure 7: RVOs (BRVO and CRVO) on an FA
  • Figure 8: Increased CRT in ME-RVO
  • Figure 9: ME Clinical Treatment Flowchart
  • Figure 10: AMD Clinical Treatment Flowchart
  • Figure 11: Eylea's Clinical Development in DME and ME-BRVO
  • Figure 12: Iluvien's and Ozurdex's Clinical Development in wAMD, dAMD, and DME
  • Figure 13: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023
  • Figure 14: Abicipar Pegol's Clinical Development in wAMD and DME
  • Figure 15: Clinical and Commercial Positioning of abicipar pegol
  • Figure 16: Fovista's Clinical Development in wAMD
  • Figure 17: Clinical and Commercial Positioning of Fovista
  • Figure 18: Squalamine's Clinical Development in wAMD and DME
  • Figure 19: Clinical and Commercial Positioning of squalamine
  • Figure 20: Lampalizumab's Development in wAMD
  • Figure 21: Clinical and Commercial Positioning of lampalizumab
  • Figure 22: Emixustat Clinical Development in dAMD
  • Figure 23: Clinical and Commercial Positioning of emixustat
  • Figure 24: Individual Drug Sales for ME in France, 2013-2023
  • Figure 25: Individual Drug Sales for AMD in France, 2013-2023
  • Figure 26: Individual Drug Sales for ME in Germany, 2013-2023
  • Figure 27: Individual Drug Sales for AMD in Germany, 2013-2023
  • Figure 28: Individual Drug Sales for ME in Italy, 2013-2023
  • Figure 29: Individual Drug Sales for AMD in Italy, 2013-2023
  • Figure 30: Individual Drug Sales for ME in Spain, 2013-2023
  • Figure 31: Individual Drug Sales for AMD in Spain, 2013-2023
  • Figure 32: Individual Drug Sales for ME in the UK, 2013-2023
  • Figure 33: Individual Drug Sales for AMD in the UK, 2013-2023
Back to Top